Table of contents

• Trial overview
• Who is being studied
• Treatments in the study
• Study phase and design
• Main outcome being measured
• What the trial means for patients

Trial overview

The source data includes one interventional clinical trial that investigates treatment for acne and lists Adapalene among the study drugs.^[1] The trial is authorised and plans to enroll 420 participants.^[1]

The study title shows that researchers are comparing oral isotretinoin with standard of care in people with moderate acne and skin of color.^[1] The brief summary says the goal is to test whether early treatment improves the severity of ARP at 6 months.^[1]

Who is being studied

The trial focuses on patients with moderate facial acne.^[1] It also specifically includes skin of color patients, which means people with darker skin tones.^[1]

The source data does not give a full list of entry rules, so only the population named in the trial record can be described here.^[1] Based on the title and summary, the study is aimed at people who need treatment for acne on the face.^[1]

Treatments in the study

Adapalene appears in the intervention list as ADAPALENE ZENTIVA 0,1 %, crème, which is a cutaneous, or skin, treatment.^[1] The record also lists other acne treatments used in the study setting, including oral isotretinoin, doxycycline, lymecycline, and other topical products.^[1]

The trial title and summary show that the main comparison is between early oral isotretinoin and the current standard of care.^[1] Adapalene is part of the treatment list, but the source data does not say that it is the main treatment being tested alone.^[1]

• Topical treatment means a medicine applied to the skin, not taken by mouth.^[1]
• Oral treatment means a medicine taken by mouth as a capsule or tablet.^[1]
• Standard of care means the usual treatment used in regular medical practice.^[1]

Study phase and design

This is a Phase 3 trial.^[1] Phase 3 studies usually involve larger groups of patients and compare treatment results in real-world-like settings.^[1]

The study type is listed as interventional, which means the research team gives treatments and measures the effects.^[1] The enrollment target is 420 participants, showing that this is a fairly large study for acne research.^[1]

Main outcome being measured

The primary outcome is the ARP severity score, measured from facial pictures, including selfies, at month 6.^[1] The score ranges from 0 to 4, where 0 means no ARP and 4 means severe ARP.^[1]

In this study, success is defined as a score below 2 at month 6, which means no or very mild ARP.^[1] The record explains that this scoring method was developed for hyperpigmented skin changes and is validated in dark skin types.^[1]

• Primary outcome is the main result the researchers want to measure.^[1]
• Validated means the method has been checked and shown to work for the group being studied.^[1]
• Hyperpigmented lesions are darker spots or patches on the skin.^[1]

What the trial means for patients

For patients, this trial shows that Adapalene is being studied in the context of acne care, especially where skin changes after acne are a concern.^[1] The study is not mainly about Adapalene alone, but about acne treatment strategies that include it among other standard options.^[1]

The most important research question is whether early treatment can improve the skin outcome measured by ARP severity at 6 months.^[1] Because the study focuses on moderate facial acne in skin of color patients, it may help answer questions that matter for this specific group.^[1]